Mayne Pharma is a specialty pharmaceutical company focused on commercialising novel and generic pharmaceuticals, offering patients better, safe, and more accessible medicines. Today, they announced that NEXTSTELLIS, a first-of-its-kind oral contraceptive with a novel estrogen is now available in Australia. NEXTSTELLIS was approved by the Therapeutic Goods Administration in November 2021 and is the first and only contraceptive pill containing a new low impact estrogen (E4), which is derived from a plant source. Combined oral contraceptives continue to be the most common method of contraception in Australia with nearly 1 million women using them.
Mayne Pharma Launch NEXTSTELLIS in Australia
You might also like
22 May 2022
Lifestyle Communities Acquire a New Site
Good news for Lifestyle Communities as they have acquired a new site in Leopold on the Bellarine Peninsula.
31 Jul 2023
Genex Releases June 2023 Quarterly Report
Genex's June quarterly report shows encouraging positive operating cashflow and a strong solar revenue.